[vc_row][vc_column width=”1/1″][mp_block_1 category_display=”root” post_sort=”date” post_limit=”3″ post_offset=”4″][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][mp_block_4 category_display=”root” post_sort=”date” post_limit=”4″ post_offset=”7″][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][vc_widget_sidebar sidebar_id=”content-ad-1″ el_class=”content-ad”][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][mp_block_6 category_display=”root” post_sort=”date” post_limit=”3″ post_offset=”11″][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][mp_block_6 category_display=”root” post_sort=”date” post_limit=”3″ post_offset=”14″][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][vc_widget_sidebar sidebar_id=”content-ad-2″][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][mp_block_6 category_display=”root” post_sort=”date” post_limit=”3″ post_offset=”18″][/vc_column][/vc_row]
Home
Recent Posts
- Nominations Open for 2022 Eurordis Black Pearl Awards
- KVD900 Slows HAE Attacks, Quickens Symptom Relief in Phase 2 Trial
- Interim Data Support Long-term Safety of Orladeyo for HAE Attacks
- Companies Join to Advance OTL-105, Potential Gene Therapy for HAE
- Impaired Smell in HAE Types 1, 2 Likely Unrelated to Gene Changes
- Centogene Sets Mission to Cure 100 Rare Diseases in Next 10 Years
- EveryLife Introduces First of Kind ‘Roadmap’ to ICD Codes
- Oral On-demand KVD900 Rapidly Reduces HAE Attack Severity
- Israel Agrees to Review BioCryst’s Marketing Request for Orladeyo
- Get Ready for NORD’s Patient and Family Forum, Set for June 26-27